IQVIA Holdings Stock - Morgan Stanley cuts rating and trims target
19.06.2026 - 17:55:34 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:50 CET. Details in the imprint.
IQVIA Holdings (US46266C1053) faces a fresh dose of analyst caution this week. Morgan Stanley has downgraded the stock to Equal-weight and cut its price target to $200 from $225, according to a recent analyst update that also favored Charles River Laboratories.
All news and analysis on IQVIA Holdings stock
Stay on top of rating changes, earnings and sector moves affecting IQVIA Holdings stock with our continuously updated coverage.
Morgan Stanley turns more cautious
Morgan Stanley’s move marks a clear shift in how the bank balances exposure within drug research and contract services. The analyst simultaneously upgraded Charles River Laboratories to Overweight and lowered IQVIA’s rating to Equal-weight while trimming its target to $200.
The note argues that upside drivers at IQVIA are less visible than at Charles River. The analyst also voices skepticism that IQVIA can expand margins meaningfully from current levels, limiting the scope for multiple expansion despite the company’s strong position in life-science data and services.
How the call fits this week’s sector picture
The rating reset comes as investors reassess contract research and data providers after a mixed stretch for healthcare and biotech funding. Morgan Stanley’s report highlights potential catalysts such as a European asset sale from Charles River to IQVIA and shifts in how big pharma manages trial data.
One risk the bank flags is that more pharmaceutical companies may move elements of clinical data management in-house. That could test demand for IQVIA’s newer AI-driven offerings, even as the company continues to emphasize technology and analytics as long-term growth pillars.
The business behind the stock
IQVIA generates revenue across advanced analytics, technology platforms and contract research services for the global life sciences industry. The group was formed in 2016 through the merger of IMS Health and Quintiles, combining large healthcare data assets with clinical trial execution capabilities.
Its portfolio spans real-world evidence solutions, clinical trial design and monitoring, and commercial analytics used by pharmaceutical and biotech customers worldwide. Against this backdrop, rating changes from major banks can influence how investors weigh IQVIA’s data-rich model against margin and growth questions.
Where the stock trades today
IQVIA Holdings shares trade on the New York Stock Exchange at around $167.70 as of the close on 06/18/2026, according to recent market data, implying a market capitalization near $28 billion.
IQVIA Holdings at a glance
- Company: IQVIA Holdings Inc.
- ISIN: US46266C1053
- WKN: A2JSPM
- Ticker: IQV
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 167.70 USD
- Market cap: 28.00 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
